Having trouble accessing articles? Reset your cache.

Sept. 26 Preclinical Quick Takes: $30M for new lung disease lab; plus AI-derived compounds from Auransa, Atomwise, and diabetes candidates

Bayer, Brigham and Mass General open lung disease-focused lab
Bayer AG (Xetra:BAYN) will invest more than $30 million over five years to fund research into new treatments for chronic lung diseases, such as chronic obstructive pulmonary disease, at a joint lab launched by the pharma, Massachusetts General

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE